CLINICAL RESEARCH

The Relationship between Reoperative Prognostic Nutritional Index Levels and Risk of In-Stent Restenosis following Cerebrovascular Bare-Metal Stent Implantation

Qiang Fang¹, Yun Yang², Jiajun Wei¹, Ligen Fan¹, Zhuoxi Xie¹, Zhuming Zhu¹ and Hao Li¹*

¹Department of Neurology, The Affiliated Hospital of Guilin Medical University, Guilin, China
²Department of Neurology, The Second Affiliated Hospital of Guilin Medical University, Guilin, China

*Corresponding author: Hao Li, Department of Neurology, The Affiliated Hospital of Guilin Medical University, Lequn Road, Guilin, Guangxi, 541000, China, Tel: 185-078-38866

Abstract

Introduction: In-stent restenosis (ISR) is a key parameter influencing long-term stent use in patients that have undergone cerebrovascular stent implantation, and it additionally impacts surgical treatment outcomes. Inflammation is a key driver of ISR incidence. To date, however, no studies have evaluated the relationship between ISR and prognostic nutritional index (PNI), which is based upon lymphocyte counts and serum albumin levels and is closely linked with inflammatory activity. In this study, we therefore assessed whether PNI levels upon admission were predictive of ISR incidence.

Methods: In total, 141 patients with a history of intracranial artery stent implantation (19.9% female) were analyzed in this study. ISR was diagnosed based upon a > 50% narrowing of the blood vessel at the site of stenting relative to the diameter following the most recent intervention. Based on these criteria, patients were separated into ISR and restenosis-free groups.

Results: ISR was observed in 36 patients (25.5%). The PNI of ISR patients upon admission was significantly lower than that of restenosis-free patients (OR = 0.901, 95% CI 0.825-0.985, P = 0.022). We additionally determined that lymphocyte count (OR = 0.495, 95% CI 0.260-0.943, P = 0.033), was independent risk factors for ISR.

Conclusion: Patients with a lower PNI level at admission was at a higher risk of suffering from ISR.

Keywords
Cerebrovascular-disease, In-stent-restenosis, Prognostic-nutritional-index, Albumin, Lymphocyte, Inflammatory response

Introduction

In patients with cerebrovascular diseases, both medications and interventional neurosurgery are the primary treatment approaches. Stent implantation, aneurysm embolization, and balloon angioplasty are all forms of percutaneous intracranial artery intervention that are implemented in certain patients. Intracranial stent implantation can lower restenosis rates via eliminating elastic retraction and negative reconstruction following balloon angioplasty. However, this approach is still limited by the incidence of in-stent restenosis (ISR), which can occur despite improvements in both implantation techniques and antiplatelet therapy in recent years.

The prognostic nutritional index (PNI) was proposed by Onodera, et al. and is computed based upon serum albumin levels and lymphocyte counts in a given patient [1]. PNI values have been successfully used as a means of gauging surgical risk and prognosis following myocardial or cerebral infarction.

At physiological concentrations, albumin is able to mediate the selective inhibition of tumor necrosis factor-induced vascular cell adhesion molecules expression. If can further suppress monocyte adhesion and transcription factor activation within endothelial cells in humans, indicating that albumin may play a key anti-inflammatory role [2,3]. Albumin additionally functions as a key antioxidant protein that can sequester roughly
70% of free radicals in serum. When these free radicals are not effectively neutralized, they can damage endothelial cells, stimulate vascular smooth muscle cell proliferation and intimal hyperplasia, and drive ISR and arterial lesion development [4]. There is prior evidence that reduced albumin levels upon hospital admission can independently predict stent restenosis in patients that undergo bare-metal stent implantation within the coronary artery [5]. There is also evidence that preoperative neutrophil-to-lymphocyte ratio (NLR) can predict ISR incidence in patients undergoing bare-metal stenting of the coronary artery, with lymphocyte count being negatively correlated with the incidence of cardiovascular events [6]. However, few studies have specifically evaluated the relationship between lymphocyte counts and ISR.

**Materials and Methods**

**Study population**

In total, 201 patients that had undergone successful intracranial artery stent implantation between May 2017 and May 2020 at our hospital were included in this study. Patients were excluded if they had a history of cancer, hematologic disease, severe kidney or liver disease, infectious disease, or inflammatory disease. Ultimately, 141 patients that had undergone intracranial stent implantation due to acute or chronic cerebrovascular stenosis, aneurysm, or arterial dissection were included in this study cohort.

Hyperlipidemic patients were those with total cholesterol ≥ 6.0 mmol/L and/or low-density lipoprotein cholesterol (LDL-C) ≥ 3.49 mmol/L. Patients were considered to have hypertension if their blood pressure was ≥ 140/90 mmHg at the time of admission, or if they had a history of hypertension even if it was presently stable and controlled using appropriate drugs. Patients were considered to have diabetes if they had a fasting blood glucose level ≥ 7.0 mmol/l, a random blood glucose level ≥ 11.1 mmol/l, or a documented history of diabetes that was controlled by drugs. Our local ethics committee approved this study, and all patients provided written informed consent to participate (the clinical trial number is 2021GLMU1AYJS016).

**Procedures**

Standard cerebral angiography and stenting were conducted via a femoral artery approach. Cerebrovascular lesions were diagnosed by experienced physicians. All patients were treated for 3-5 days prior to surgery with oral aspirin (0.1 g) and clopidogrel (75 mg). Following femoral artery puncture, patients were intravenously administered heparin (2/3 mg/kg), with additional heparin being injected as needed to maintain an activated partial thromboplastin time (APTT) > 120 seconds. Successful stent implantation was defined by a lack of major complications and by a stent stenosis diameter of < 30%.

**Laboratory assays**

Prior to stent implantation, venous blood samples were collected from each patient. The samples were analyzed for the following parameters using standard laboratory techniques: lymphocyte counts (TLC), WBC, platelet count, plasma albumin (ALB), creatinine, and fasting blood lipids (including triglycerides, total cholesterol, LDL-C, and HDL-C). PNI was calculated as follows: PNI = ALB (g/l) + 5 * TLC [7]. ISR was diagnosed based upon a > 50% narrowing of the blood vessel at the site of stenting relative to the diameter following the most recent intervention [8].

**Statistical analysis**

SPSS V26.0 version was used for all data analyses. Categorical variables are given as counts with percentages and were compared via Chi-square test and Fisher’s exact test, while continuous variables are means ± standard deviations or medians with interquartile ranges and quartile ranges and were compared via Student’s t-test and Mann-Whitney U tests as appropriate. The goodness of fit was evaluated via the Hosmer-Lemeshow test. The relationships between variables were assessed through Pearson correlation analysis. Independent predictors of ISR were identified through multiple regression analysis.

### Table 1: The character of clinical data of patients in the no-ISR group and ISR group.

<table>
<thead>
<tr>
<th>Variable</th>
<th>No-ISR (N = 105)</th>
<th>ISR (N = 36)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, Years</td>
<td>59 ± 15</td>
<td>63 ± 9.0</td>
<td>0.059</td>
</tr>
<tr>
<td>Hypertension</td>
<td>58 (55.2%)</td>
<td>17 (47.2%)</td>
<td>0.406</td>
</tr>
<tr>
<td>Current smokers</td>
<td>69 (65.7%)</td>
<td>19 (52.8%)</td>
<td>0.167</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>57 (54.3%)</td>
<td>16 (44.4%)</td>
<td>0.308</td>
</tr>
<tr>
<td>Family history of stroke</td>
<td>12 (11.4%)</td>
<td>3 (8.3%)</td>
<td>0.603</td>
</tr>
<tr>
<td>Heart rate, Beats/min</td>
<td>81 ± 19</td>
<td>83 ± 17</td>
<td>0.577</td>
</tr>
<tr>
<td>Pre-hospital treatments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAPT</td>
<td>23 (21.9%)</td>
<td>8 (22.2%)</td>
<td>0.968</td>
</tr>
<tr>
<td>Reduce blood press</td>
<td>28 (26.7%)</td>
<td>10 (27.8%)</td>
<td>0.897</td>
</tr>
<tr>
<td>Hypolipemic</td>
<td>17 (16.2%)</td>
<td>7 (19.4%)</td>
<td>0.654</td>
</tr>
</tbody>
</table>

*P<0.05, with statistical difference; No ISR: No in stent restenosis; ISR: In stent restenosis; DAPT: Dual antiplatelet therapy.*
count (OR = 0.495, 95% CI: 0.260-0.943, P = 0.033) were all associated with ISR incidence (Table 3).

Using the ROC curve (Figure 2), we found that the optimal cut-off PNI value at admission in the overall patient population for the prediction of ISR was 52.5, yielding a sensitivity of 80.6% and a specificity of 67.6% (AUC: 0.772, 95% CI: 0.679-0.865, P < 0.05).

Discussion

Herein, we evaluated the prognostic relevance of PNI levels on admission as predictors of ISR incidence in patients that underwent successful bare-metal stent implantation. Through this approach, we determined that lower PNI upon admission was associated with a greater risk of ISR development.

Stent implantation within the intracranial artery is the most prevalent form of vascular reconstructive surgery in cerebrovascular disease patients. However, the long-term efficacy of this approach is limited by ISR incidence [9]. Stent restenosis is difficult to remove and is associated with increased costs and adverse event incidence [10]. ISR exhibits a multifactorial etiology and regression and logistic regression analyses. The sensitivity and specificity of PNI levels as a predictor of ISR were assessed using receiver operating characteristic (ROC) curves, which were additionally used to identify optimal PNI cut-off values for ISR prediction. P < 0.05 was the significance threshold.

Table 2: Comparison of blood indexes between ISR group and no-ISR group.

<table>
<thead>
<tr>
<th>变量</th>
<th>No-ISR (N = 105)</th>
<th>ISR (N = 36)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC, 10^9/L</td>
<td>7.3 ± 2.2</td>
<td>7.4 ± 2.3</td>
<td>0.816</td>
</tr>
<tr>
<td>PLT, 10^9/L</td>
<td>218 ± 41</td>
<td>219 ± 46</td>
<td>0.903</td>
</tr>
<tr>
<td>TLC, 10^9/L</td>
<td>2.1 ± 0.1</td>
<td>1.8 ± 0.1</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>ALB, 10^9/L</td>
<td>41.2 ± 0.3</td>
<td>40.5 ± 0.6</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>creatinine, umol/L</td>
<td>81 ± 21</td>
<td>79 ± 28</td>
<td>0.696</td>
</tr>
<tr>
<td>TC, mmol/L</td>
<td>3.6 ± 1.3</td>
<td>3.8 ± 1.1</td>
<td>0.410</td>
</tr>
<tr>
<td>LDL-C, mmol/L</td>
<td>2.7 ± 0.9</td>
<td>2.9 ± 0.8</td>
<td>0.239</td>
</tr>
<tr>
<td>TG, mmol/L</td>
<td>1.9 ± 1.1</td>
<td>1.8 ± 0.9</td>
<td>0.624</td>
</tr>
<tr>
<td>PNI</td>
<td>51.7 ± 0.5</td>
<td>49.5 ± 0.8</td>
<td>&lt; 0.001*</td>
</tr>
</tbody>
</table>

*P < 0.05, with statistical difference; No ISR: No in stent restenosis; ISR: In stent restenosis; WBC: White blood cell; PLT: Platelet count; TLC: Lymphocyte count; ALB: Albumin; TC: Total cholesterol; LDL-C: Low density lipoprotein cholesterol; TG: Triglyceride; PNI: Prognostic nutritional index

Table 3: Results of binary logistics regression for ISR.

<table>
<thead>
<tr>
<th>Variable</th>
<th>β</th>
<th>SE(βi)</th>
<th>Waldχ²</th>
<th>OR(95%CI)*</th>
<th>P值 (P-value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLC, 10^9/L</td>
<td>-0.704</td>
<td>0.329</td>
<td>4.565</td>
<td>0.495 (0.260-0.943)</td>
<td>0.033*</td>
</tr>
<tr>
<td>ALB, 10^9/L</td>
<td>-0.065</td>
<td>0.060</td>
<td>1.167</td>
<td>0.937 (0.832-1.055)</td>
<td>0.280</td>
</tr>
<tr>
<td>PNI</td>
<td>-0.104</td>
<td>0.045</td>
<td>5.247</td>
<td>0.901 (0.825-0.985)</td>
<td>0.022*</td>
</tr>
</tbody>
</table>

*P < 0.05, with statistical difference; TLC: Lymphocyte count; ALB: Albumin; PNI: Prognostic nutritional index

Results

There were no significant differences in the clinical baseline characteristics between the two groups (Table 1).

The results of preoperative blood tests for these patients are compiled in Table 2. Both lymphocyte counts (P < 0.001) and serum albumin levels (P < 0.001) were lower in patients in the ISR group than in the restenosis-free group. PNI levels were significantly lower in the ISR group than in the restenosis-free group (Figure 1; 49.5 ± 0.8 vs. 51.7 ± 0.5, P < 0.001). The WBC, platelet count, creatinine, and fasting blood lipids were no significantly in the two groups.

Multiple factor analysis revealed that PNI level (OR = 0.901, 95% CI: 0.825-0.985, P = 0.022), lymphocyte count (OR = 0.495, 95% CI: 0.260-0.943, P = 0.033) were all associated with ISR incidence (Table 3).

Using the ROC curve (Figure 2), we found that the optimal cut-off PNI value at admission in the overall patient population for the prediction of ISR was 52.5, yielding a sensitivity of 80.6% and a specificity of 67.6% (AUC: 0.772, 95% CI: 0.679-0.865, P < 0.05).

Figure 1: Comparison of TLC, ALB and PNI levels between patients with and without in-stent restenosis.
Lymphocytes are key mediators of immune responses [16], and low lymphocyte counts are an independent risk factor associated with cerebrovascular and cardiovascular disease incidence [17]. Kanbay, et al. also found that lower lymphocyte counts are related to dysregulated inflammatory responses and with the incidence of cerebrovascular and cardiovascular disease [18]. Lymphocytes regulate inflammatory immune responses in part via secreting cytokines [19], and there is increasingly robust evidence suggesting that chronic low-grade inflammation is a key driver of ISR pathogenesis [20].

This study has multiple limitations. For one, this was a single-center retrospective analysis of only patients implanted with bare-metal stents that experienced restenosis, and because of the small sample size, the bias factors of case selection cannot be completely excluded. In addition, our sample size was limited. Furthermore, continuous measurements were not made and so we were not able to monitor changes of time in a robust manner. As such, future prospective randomized clinical trials will be essential to assess the clinical applicability of our findings.

Conclusions

Overall, our results suggest that lower PNI values and lower lymphocyte count upon hospital admission are associated with increased ISR risk in patients undergoing bare-metal stent implantation.

Statements

Acknowledgment

We do appreciate the efforts of the intervention team in neurology department of The Affiliated Hospital of Guilin Medical University, in assisting in the collection of clinical cases.

Statement of ethics

Subjects (or their parents or guardians) have given their written informed consent. The institutional review board approved the exemption in accordance with the Ethical Guidelines for the Affiliated Hospital of Guilin Medical College, Ethical review of biomedical research involving human beings (the clinical trial number is 2021GLMU1AYJS016).

Conflict of interest statement

The authors have no conflicts of interest to declare.

Funding sources

This research was supported by the doctoral foundation of Guilin scientific research and technology development program (No. 2017010911).

Author contributions

Q.F. and Y.Y. contributed equally to the preparation
of this article; Q.F.: Study design, case collection, data collection, statistical analysis, and dissertation writing; Y.Y.: Shared the scientific discussion and contributed in the writing of the article; H.L.: Research guidance, study design, and case collection; J.J.W., L.G.F, Z.X.X. and Z.M.Z.: case collection.

References